TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6433770
Drug: HB 420
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HB 420 (3.5 mg twice a day)
Study: 26954726
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of female emotional tears
Study: 26545199
Drug: 1,25(OH)2D3 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25(OH)2D3 (2 μg daily for 7 days)
Study: 19716512
Drug: Immediate post
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate post space preparation using heated instrument (Group A)
Study: 19716512
Drug: Delayed post
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed post space preparation after 1 week with Gates‐Glidden drills (Group B)
Study: 9273186
Drug: CEBI 140
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEBI 140 trial: Combination of daily cisplatin (6 mg/m2 per day, total 144 mg/m2), vindesine (2.5 mg/m2 once a week, total 15 mg/m2), bifractionated radiotherapy (60 Gy/48 fractions/6 weeks) followed by two cycles of cisplatin (120 mg/m2) and three cycles of vindesine (6 mg/m2).
Study: 9273186
Drug: CEBI 142
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEBI 142 trial: Combination of cisplatin (100 mg/m2 at d1 and d24, total 200 mg/m2), vinblastine (4 mg/m2 at d1 and d24, total 8 mg/m2), 5-fluorouracil (1,000 mg/m2 from d1 to d3 and from d24 to d26, total 6,000 mg/m2), bifractionated radiotherapy (two series of 21 Gy/14 fractions/9 days, 11 days apart) followed by surgical excision.
Study: 26845098
Drug: 300,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300,000 IU of cholecalciferol administered 4 days before surgery
Study: 26845098
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered during the first extraction (control group)
Study: 19583756
Drug: Five sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five sessions of cognitive behavioural therapy (CBT) performed by dentists
Study: 19583756
Drug: One session
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One session of cognitive behavioural therapy (CBT) performed by dentists
Study: 16960445
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy with bisoprolol
Study: 16960445
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy with placebo
Study: 16960445
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin therapy with bisoprolol
Study: 16960445
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin therapy with placebo
Study: 16960445
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (both with bisoprolol and placebo)
Study: 11476119
Drug: Risperidone (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (up to 10 mg/day)
Study: 11476119
Drug: Haloperidol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (up to 20 mg/day)
Study: 1976678
Drug: Chlorhexidine preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine preparations
Study: 487693
Drug: D-amphetamine, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-amphetamine, 10 mg orally
Study: 487693
Drug: Pentazocine, 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine, 45 mg intramuscularly
Study: 487693
Drug: Nefopam (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (both doses)
Study: 31079746
Drug: No information
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: No information treatment (control)
Study: 27829323
Drug: 25 ml
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 ml of 6.7% maltodextrin solution (MALT)
Study: 25135598
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (controlled lighting: lights on at 06:30 and off at 22:30, blue-enriched light in the morning, red-enriched light in the afternoon/evening)
Study: 24252551
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (V.A.C.®)
Study: 24252551
Drug: Standard conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard conventional wound therapy
Study: 17146380
Drug: 10 to
Normalized name: RE-10 Topical Wash
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 to 100 mg/5 mL, 10 mL codeine/guaifenesin every 6 hours standing dose while awake
Study: 2830407
Drug: RA‐233 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RA‐233 plus chemotherapy
Study: 31453490
Drug: Prolotherapy injections
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolotherapy injections (ultrasound-guided, 5 points, 3 times every 21 days)
Study: 23660686
Drug: Bedtime medication
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime medication
Study: 23660686
Drug: Morning medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning medication
Study: 21937486
Drug: Thermostatic control
Normalized name: collagen hemostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermostatic control sterilisation programme (heating water to 65°C during 00:00‐06:00 h and to 50°C from 06:00 to 00:00 h daily)
Study: 18335154
Drug: Bupivacaine injection
Normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine injection into the subcutaneous and muscular layers around the incision site
Study: 17010727
Drug: Lidocaine jelly
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine jelly instillation (2 mL)
Study: 8068604
Drug: Conventional immunoreactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunoreactive insulin assay
Study: 8068604
Drug: Specific Linco
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific Linco insulin assay
Study: 3284270
Drug: Alcuronium 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcuronium 0.03 mg/kg
Study: 3284270
Drug: Alcuronium 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcuronium 0.03 mg/kg (3-min group)
Study: 3284270
Drug: Alcuronium 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcuronium 0.03 mg/kg (2- and 3-min groups)
Study: 9164003
Drug: b.i.d. group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: b.i.d. group: one capsule of slow‐release nicardipine, 20 mg, twice a day, three months
Study: 9164003
Drug: t.i.d. group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: t.i.d. group: one tablet of regular nicardipine, 20 mg, three times a day, three months
Study: 6237116
Drug: Flutamide (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (750 mg/day)
Study: 6237116
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (100 mg/day)
Study: 30762694
Drug: Single-injection bupivacaine
Normalized name: bupivacaine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection bupivacaine interscalene block with adjuvant clonidine, dexamethasone, and buprenorphine; multimodal analgesia including acetaminophen, NSAIDs, and opioids.
Study: 27305512
Drug: Euclea natalensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euclea natalensis gel
Study: 24310343
Drug: lutein/zeaxanthin, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: lutein/zeaxanthin, 10 mg/2 mg
Study: 22290953
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg TID on days 9 to 15
Study: 22290953
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg BID on days 9 to 15
Study: 22290953
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg TID on days 9 to 15
Study: 22290953
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg TID on days 1 to 8
Study: 22290953
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses (400 mg BID and 400 mg TID)
Study: 15751772
Drug: Nevirapine (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine (once or twice daily)
Study: 15751772
Drug: Combination with
Normalized name: Iron in combination with folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination with lamivudine and stavudine
Study: 11892685
Drug: Homeopathic Arnica
Normalized name: ARNICA MONTANA WHOLE 6 [hp_X] ORAL LOZENGE [Homeopathic Arnica Drops]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic Arnica tablets and herbal Arnica ointment
Study: 10459957
Drug: Zidovudine 300
Normalized name: zidovudine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine 300 mg tablet twice daily from 36 weeks' gestation and every 3 h from onset of labour until delivery
Study: 7887759
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (unrelated discussion on non-steroidal drug use)
Study: 3896278
Drug: Nicardipine 30
Normalized name: niCARdipine 30 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 30 mg three times daily
Study: 111886
Drug: High-dose intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intermittent subcutaneous injections
Study: 25801095
Drug: Intravenous peginterferon
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous peginterferon alfa-2a 180 μg, once weekly for 2 weeks
Study: 25801095
Drug: Intravenous peginterferon
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous peginterferon alfa-2a 180 μg, twice weekly for 2 weeks
Study: 25801095
Drug: Subcutaneous peginterferon
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous peginterferon alfa-2a 180 μg, once weekly for 2 weeks
Study: 25801095
Drug: Subcutaneous peginterferon
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous peginterferon alfa-2a 180 μg, twice weekly for 2 weeks
Study: 16713391
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of industrially produced TFA (IP‐TFA)
Study: 16713391
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g n‐3 PUFA
Study: 11425821
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg injection of triptorelin (group 1)
Study: 11425821
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg triptorelin daily reduced to 50 microg at the start of FSH stimulation (group 2)
Study: 3304156
Drug: Intravenous ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ampicillin
Study: 27711918
Drug: Bevacizumab with
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab with laser treatment
Study: 21706324
Drug: Cisplatin 25
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 25 mg/m² intravenously on days 1-3 and gemcitabine 1,000 mg/m² on days 1 and 8, every 3 weeks for two cycles as neoadjuvant chemotherapy, followed by two cycles as adjuvant chemotherapy after radiotherapy.
Study: 21706324
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus gemcitabine chemotherapy and intensity-modulated radiotherapy
Study: 20167174
Drug: Paradigm Veo
Normalized name: Veopoz
DrugBank: Pozelimab (DB15218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paradigm Veo insulin pump with new calibration algorithm
Study: 18175748
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g vitamin C daily supplementation in humans
Study: 18175748
Drug: 0.24 mg/cm2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.24 mg/cm2 body surface area vitamin C daily supplementation in rats
Study: 2859523
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy (4000 or 4800 rad)
Study: 2859523
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (fluorouracil and semustine [methyl‐CCNU])
Study: 2859523
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of radiation therapy and chemotherapy
Study: 2859523
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant therapy (control group)
Study: 25348047
Drug: Conventional intensive
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional intensive insulin therapy (CIIT)
Study: 24510314
Drug: Hepatic intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hepatic intra-arterial fotemustine (HIA) at 100 mg/m² on days 1, 8, 15 (and 22 in HIA arm only) as induction, and after a 5-week rest period every 3 weeks as maintenance.
Study: 24510314
Drug: Intravenous fotemustine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fotemustine (IV) at 100 mg/m² on days 1, 8, 15 as induction, and after a 5-week rest period every 3 weeks as maintenance.
Study: 22300292
Drug: Retinal regeneration
Normalized name: retinaldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinal regeneration therapy laser
Study: 15956273
Drug: Galantamine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (16 mg, 24 mg, or 32 mg daily)
Study: 2169587
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with cisplatin (100 mg/m² on days 1 and 29) and vinblastine (5 mg/m² on days 1, 8, 15, 22, and 29) followed by radiation therapy (60 Gy over 6 weeks)
Study: 2169587
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy alone (60 Gy over 6 weeks)
Study: 2169587
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with cisplatin and vinblastine
Study: 30747964
Drug: Paracetamol (acetaminophen)
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol (acetaminophen) 1000 mg plus ibuprofen 400 mg (PCM + IBU)
Study: 30747964
Drug: Paracetamol 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1000 mg (PCM)
Study: 30747964
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg (IBU)
Study: 30747964
Drug: Half-strength paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-strength paracetamol 500 mg plus ibuprofen 200 mg (HS-PCM + IBU)
Study: 30747964
Drug: Paracetamol (PCM)
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol (PCM) alone
Study: 30747964
Drug: Half-strength paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-strength paracetamol plus ibuprofen (HS-PCM + IBU)
Study: 30747964
Drug: Ibuprofen alone
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen alone (IBU)
Study: 30747964
Drug: Paracetamol alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol alone (PCM)
Study: 30747964
Drug: Groups receiving
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups receiving ibuprofen (IBU)
Study: 19999017
Drug: Salbutamol and
Normalized name: salbutamol and budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol and ipratropium bromide administered by device of measured doses and space chamber
Study: 14981346
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg once daily + ASA 75 mg once daily
Study: 9511113
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg twice daily for 2 to 3 weeks)
Study: 9511113
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (250 mg twice daily for 2 to 3 weeks)
Study: 7974935
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day propiverine
Study: 7974935
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day propiverine
Study: 7974935
Drug: 45 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg/day propiverine
Study: 7974935
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day propiverine
Study: 7974935
Drug: Propiverine (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine (doses of 15, 30, 45 and 60 mg/day)
Study: 4908342
Drug: 1-adamantanamine hydrochloride
Normalized name: 1-adamantanamine
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-adamantanamine hydrochloride (aminoadamantane) 100 mg every 12 hours for 10 days
Study: 28477414
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin therapy
Study: 28477414
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin therapy
Study: 28477414
Drug: Prandial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prandial insulin therapy
Study: 23648946
Drug: Ambrisentan, 10
Normalized name: Ambrisentan, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan, 10 mg/d
Study: 19826286
Drug: Low-load resistance
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-load resistance training with slow movement and tonic force generation (LST) at approximately 60% 1RM, 3-second lifting, and 3-second lowering, performed twice a week for 13 weeks
Study: 19826286
Drug: High-intensity exercise
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity exercise at normal speed (HM) at 85% 1RM, 1-second lifting, 1-second lowering, and 1-second relaxed movement, performed twice a week for 13 weeks
Study: 11579330
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg of morphine following induction and placebo saline during peritoneal closure
Study: 11579330
Drug: Placebo saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo saline following induction and 0.15 mg/kg of morphine during peritoneal closure
Study: 26296862
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol administered via dry powder inhalers
Study: 21604899
Drug: Short-term treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term treatment for GAD patients
Study: 21604899
Drug: Short-term treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term treatment for GAD patients (Overly Nurturant subtype)
Study: 21604899
Drug: Short-term treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term treatment for GAD patients (Intrusive subtype)
Study: 21604899
Drug: Short-term treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term treatment for GAD patients (Socially Avoidant subtype)
Study: 21604899
Drug: Short-term treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term treatment for GAD patients (Nonassertive subtype)
Study: 12625833
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine oestrogen (CEE; 0.625 mg/day; n = 14)
Study: 12625833
Drug: Raloxifene (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (150 mg/day; n = 13)
Study: 10658376
Drug: Heparin-bonded circuit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded circuit
Study: 8557867
Drug: 0.25 g
Normalized name: AMICAR 0.25 GM/mL Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 g nitrogen (N)/kg Ideal Body Weight (IBW)
Study: 8557867
Drug: 0.12 g
Normalized name: OLIVE OIL 0.12 g in 10 mL VAGINAL SPRAY [MediORO W]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12 g nitrogen (N)/kg Ideal Body Weight (IBW)
Study: 8557867
Drug: 0.18 g
Normalized name: MENTHOL 0.18 g in 100 TOPICAL GRANULE [Cough Drops]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.18 g nitrogen (N)/kg Ideal Body Weight (IBW)
Study: 2128866
Drug: Colestyramine 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestyramine 16 g
Study: 488523
Drug: sulphinpyrazone (600‐800
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulphinpyrazone (600‐800 mg daily)
Study: 25860005
Drug: Bicyclol 75
Normalized name: alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol
DrugBank: Biperiden (DB00810)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicyclol 75 mg/day (25 mg three times daily) in conjunction with glucurolactone 600 mg/day (200 mg three times daily)
Study: 25860005
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving glucurolactone 600 mg/day (200 mg three times daily) only
Study: 15789978
Drug: Oral‐B Indicator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B Indicator toothbrush
Study: 11748775
Drug: haloperidol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol (0.5 to 2 mg/day)
Study: 11748775
Drug: risperidone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: risperidone (0.5 to 2 mg/day)